New Type of Blood Thinner OKd by FDA Panel

Thursday, 16 Jan 2014 08:34 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

The panel voted 10-1 in favor of the drug, which would, if approved, be sold under the brand name Zontivity. The FDA is not bound to follow the advice of its advisory panels but typically does so.

Results from a trial known as TRA 2P were "robust," panelists said, and justified approval for patients who had suffered a heart attack.

They agreed with the company that the drug should not be used in patients with a history of stroke, since there was an increased risk of bleeding in the brain in this group of patients.

"I think this drug addresses a real unmet medical need," said Dr. Philip Sager, consulting professor of medicine at Stanford University School of Medicine.

The vote followed a positive analysis by reviewers for the FDA, whose report, published on Monday, also recommended the drug be approved.

Vorapaxar works by preventing blood cells, or platelets, from clumping together and forming clots in the arteries, which can lead to heart attacks.

Other anti-platelets include aspirin and Plavix, which is made by Bristol-Myers Squibb Co. Merck's drug works in a different way, by inhibiting a receptor known as PAR-1.

The drug increased the overall risk of bleeding in clinical trials, though the risk in patients who had not had a stroke did not outweigh the drug's benefit, panelists said.

Still, Dr. Sanjay Kaul, a cardiologist and professor at UCLA School of Medicine who voted in favor of approval, urged the FDA to "do its due diligence" around the bleeding risk.

Each year about 190,000 Americans have a second heart-related event, according to Merck. Standard therapy to prevent a second episode often includes treatment with aspirin and Plavix. Vorapaxar would be given in addition to standard treatment.

"The results of today's advisory committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack," Dr. Daniel Bloomfield, who leads Merck's cardiovascular research, said in a statement. "We look forward to working with the FDA as it completes its review."

Merck has proposed that the drug's label urge caution when prescribing the drug for patients who weigh less than 132 pounds since the risk of bleeding in these patients appears to be higher than in heavier patients.
 
Panelists could not reach a consensus recommendation on how lower-weight patients should be treated. Representatives from the FDA said they will continue to discuss the matter before making their final ruling.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Older People Sleep Less - Now We Know Why

Wednesday, 20 Aug 2014 17:33 PM

A group of brain cells collectively act as a 'sleep switch' that may account for why so many older people have difficult . . .

Mislabeled Fish Could Give You Mercury Poisoning: Study

Wednesday, 20 Aug 2014 17:27 PM

A new study of mislabeled fish sold at retailers in 10 states finds that it can expose consumers to high levels of the h . . .

10 Questions to Ask After Cancer Diagnosis

Wednesday, 20 Aug 2014 17:21 PM

A cancer diagnosis is always difficult. But getting answers to 10 key questions can help patients mobilize their efforts . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved